CVS Health Corp (CVS) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

CVS Health Corp (CVS)

104.72

-0.09 (0.09%)

as of Jul 2, 2026, 8:00:00 pm Market Open.

409 watching

Investor Insights

Jul 2, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has recently shown promising signs of recovery, with a notable increase in earnings and revenues leading to a significant share price jump. While some analysts praise the turnaround story attributed to effective management and a strategic pivot towards health services, caution is advised due to the persistent challenges in the retail pharmacy sector and overall weak visibility in quarters ahead. The stock appears to be undervalued compared to its peers, particularly in the context of its healthcare sector rivals. Recent improvements in its managed care business are encouraging, coupled with an impressive performance in pharmacy sales, which have surged by 18% year over year. Overall, a mixed outlook persists, balancing optimism about its strategic shifts against the backdrop of previous performance declines.

Consensus

Cautious

Valuation

Undervalued

Similar

WBA

PAST TOP PICK

(A Top Pick Jan 22/21, Up 46%) Trades at 13x earnings. Still a long way to go. He's very big on pharmacies, as they're delivering more and more services since it's cheaper than via hospitals.

Wealthica Track your Stocks in your Watch List

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 55.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We now recommend trailing up the stop (from $82) to $95. If triggered, this would all but guarantee a net investment gain of 30%, when combined with our previous recommendation to cover half.

PAST TOP PICK

(A Top Pick Jan 19/21, Up 42%) Debt is manageable. Free cashflow of about 13B. Well capitalized. Insurance, pharmacy with HealthHub, pharmacy benefit manager. Not expensive at 13x earnings.

BUY

Has done well, raising estimates for 2022. Redefined itself, and the market's realizing it's more than just a drugstore. Centred around health wellness. Trades at 12x earnings. Good cashflow, decent dividend.

HOLD

The PE is still attractive. CVS is adding more health services in their drug stores. Covid vaccinations encourage consumers to buy more items in their stores when they visit. Still a hold and you'll get a decent return. Still some upside here.

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Recently selected as a top pick by both our research editor Michael O'Reilly and Chris Bulmas. Very successful during the pandemic. Social media mentions increased 538% these last 24h.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 37.69%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We recommend trailing up the stop (from $70) to $82. If triggered this would result in a net investment gain over 21%, when combined by our previous recommendation to cover half.

COMMENT

They report Wednesday. They've been a roll because of the Covid vaccine and superior execution compared to Walgreens. But can they continue their streak as the pandemic winds down? They do have a huge health insurance business.

PAST TOP PICK

(A Top Pick Feb 26/20, Up 39%) He still likes it. It has a unique business model: a pharmacy, pharmacy benefit management (PBM) and health insurer. Pays a good dividend, diversified and trades around 10x earnings. Free-cash flow yield is almost 9%. It's a durable business.

BUY

It's cheap, and trades well below the market multiple. Booster shots will be a big benefit to CVS.

BUY

Vertically integrated, growing dynamically. CVS has health insurance with Aetna, pharmacy benefit manager with CareMark, and HealthHub offering in-store diagnostics. Better choice than WBA.

PAST TOP PICK

(A Top Pick Aug 21/20, Up 34%) Absolutely he'll stick with it. Trades at a fine PE. It's not just pharmacies but health insurance to add up to a vertical health business.

HOLD

WBA has operations in the US and UK. Stays in drug retail and expands geographically. Doesn't grow quickly, but it's not an income stock either. Growth profile not attractive. She owns CVS instead, with its vertically integrated strategy.

PAST TOP PICK

(A Top Pick Jun 29/20, Up 32%) They became big after buying Aetna. They're broadening offering within stores to offer services like nurse practitioners. They think beyond just being a drug store. They're well-positioned in their industry. Take a long-term view, but you can buy this at current prices.

BUY

He prefers CVS to WBA. WBA has spun its wheels a bit. CVS has better management, and it's vertically integrated with Aetna and its pharmacy benefit manager. As the pandemic eases, its revenues from Covid will shift to other areas, such as HealthHUB for chronic conditions.

Showing 151 to 165 of 464 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Ivana Delevska

Spear Advisors LLC

Jim Cramer - Mad Money

CNBC

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

CVS Health Corp (CVS)